Li Mei Poon

机构：National University Cancer Institute, Singapore, National University Hospital, National University Health System

发表论文 41 篇 · 总被引 852 次 · h-index 14

代表论文

• Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS (2022 · Haematologica · 被引 83)
• Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma (2024 · Annals of Oncology · 被引 81)
• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 52)
• Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma (2019 · Cancer Medicine · 被引 45)
• Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma (2020 · Blood Cancer Journal · 被引 38)
• Immunoglobulin M Paraproteinaemias (2020 · Cancers · 被引 19)